-
BioPharma Dive – AI / Data2 weeks agoRA Capital targets China with latest SPAC deal
The prominent investor aims to merge its latest special purpose acquisition company with a Chinese biotech, according to a securities filing.
-
BioPharma Dive – AI / Data2 weeks ago
Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases
Acquiring Ouro Medicines, which launched last year, hands Gilead an antibody designed to bind to BCMA and CD3, a pair of immune cell proteins that are...
-
BioPharma Dive – AI / Data2 weeks agoImmutrin raises $87M to advance drug for progressive heart disease
The fresh funding will help the biotech startup advance a candidate to treat a genetic disorder, “ATTR-CM,” that has become a battleground for companies like Pfizer,...
-
BioPharma Dive – AI / Data2 weeks agoKaryopharm myeloma drug yields mixed data in myelofibrosis trial
Xpovio combined with Incyte’s Jakafi helped on one key measure but missed on other goal in a disorder that, by one analyst’s estimates, could triple the...
-
BioPharma Dive – AI / Data2 weeks agoHow former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup
Cohen says he looked at around two dozen companies since Acorda wound down. Oryon Cell Therapies, with its funding, data and “autologous” approach, stood out amongst...
-
BioPharma Dive – AI / Data2 weeks agoApogee strengthens case for longer-lasting eczema drug
Company shares climbed by more than 20% on Phase 2 study results suggesting the therapy could provide sustained relief when administered once every three or six...
-
BioPharma Dive – AI / Data2 weeks agoPfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results
The partners said the shot produced “clinically meaningful” efficacy despite missing its main study objective, a finding they blamed on a lower-than-expected rate of infections during...
-
BioPharma Dive – AI / Data2 weeks agoFDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares
Industry executives can share their views on the “national priority” program at a June meeting. Elsewhere, Sanofi licensed a T cell engager and Acorda’s former CEO...
-
BioPharma Dive – AI / Data2 weeks ago
Risk, readiness and resilience
The location secret behind pharma’s most reliable East Coast expansion corridor.
-
BioPharma Dive – AI / Data3 weeks agoEarendil Labs, an AI-powered drugmaker, hauls in $787M
The hefty funding will support a U.S.- and China-based startup that’s amassed a pipeline of nearly 20 drugs and formed two lucrative partnerships with Sanofi.
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
